Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Drugs
Published in:

05-11-2024 | Plaque Psoriasis | AdisInsight Report

Vunakizumab: First Approval

Author: Susan J. Keam

Published in: Drugs | Issue 11/2024

Login to get access

Abstract

Vunakizumab (安达静®) is a subcutaneous (SC) recombinant anti-interleukin (IL)-17A humanized monoclonal IgG1/κ antibody being developed by Suzhou Suncadia Biopharmaceutical Co., Ltd (a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd) for the systemic treatment of autoimmune diseases related to the IL-17 pathway, including psoriasis, ankylosing spondylitis and psoriatic arthritis. In August 2024, vunakizumab was approved in China for the treatment of adult patients with moderate-to-severe plaque psoriasis who are suitable for systemic treatment or phototherapy. This article summarizes the milestones in the development of vunakizumab leading to this first approval for the systemic treatment of moderate-to-severe plaque psoriasis.
Appendix
Available only for authorised users
Literature
1.
Zhang C, Yan K, Diao Q, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022;87(1):95–102.CrossRefPubMed
2.
Menter A, Krueger GG, Paek SY, et al. Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb). 2021;11(2):385–400.CrossRefPubMedPubMedCentral
3.
Proft F, Duran TI, Ghoreschi K, et al. Treatment strategies for spondyloarthritis: implementation of precision medicine - or “one size fits all” concept? Autoimmun Rev. 2024;23(10): 103638.CrossRefPubMed
4.
Committee on Psoriasis Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatol. 2023;56(7):573-625.
5.
Jiangsu Hengrui Medicine Co Ltd. Milestone in chronic disease innovation! Hengrui's first autoimmune innovative drug, vunakizumab, was approved for marketing [media release]. 27 Aug 2024. https://​www.​hengrui.​com/​.
6.
Suzhou Suncadia Biopharmaceutical Co Ltd. Vunakizumab: Chinese prescribing information. Suzhou: Suzhou Suncadia Biopharmaceutical Co Ltd; 2024.
7.
Jiangsu Hengrui Medicine Co Ltd. Hengrui Medicine's innovative drug vunakizumab is approved for clinical trials for the treatment of moderate to severe plaque psoriasis in children and adolescents. [media release]. 8 Aug 2024. https://​www.​hengrui.​com/​.
8.
9.
Xu J, Yan K, Han L, et al. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial [abstract no. 115]. In: 32nd EADV Congress 2023. 2023.
10.
Huang F, Zhu J, Zhao C, et al. Vunakizumab in active ankylosing spondylitis: a randomized, double-blind, adaptive, seamless, phase 2/3 study [abstract no. POS0803]. Ann Rheum Dis. 2024;83(Suppl 1):904-905.
Metadata
Title
Vunakizumab: First Approval
Author
Susan J. Keam
Publication date
05-11-2024
Publisher
Springer International Publishing
Published in
Drugs / Issue 11/2024
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-024-02110-8

Other articles of this Issue 11/2024

Axatilimab: First Approval

  • AdisInsight Report

Efgartigimod: A Review in Generalised Myasthenia Gravis

Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer’s Disease and Associated Sleep Disorders

How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder

Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action

GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy